
QNCX Stock Forecast & Price Target
QNCX Analyst Ratings
Bulls say
Quince Therapeutics is well positioned for success with their novel drug/device combination therapy, eDSP, as seen in the promising results from the ATTeST trial and the potential for expansion into other rare diseases. However, the recent failure in the Phase 3 NEAT trial has caused a significant drop in the company's stock price. Further exploration of options and a conservative approach to cash management may lead to a rebound in the stock value in the future.
Bears say
Quince Therapeutics is facing significant risks, as their only pipeline candidate, eDSP, has shown disappointing results in the Phase 3 ATTeST trial for A-T. This raises concern about the drug's efficacy and the potential for further market share and valuation erosion. Additionally, the company's lack of approved drugs and limited visibility into its strategic roadmap may keep investor sentiment subdued. The success of their eDSP program in the ongoing Phase 3 NEAT trial will be critical to their future success and ability to raise additional capital.
This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
QNCX Analyst Forecast & Price Prediction
Start investing in QNCX
Order type
Buy in
Order amount
Est. shares
0 shares